Jean-Yves Pierga, MD, Institut Curie, Paris, France, discusses the benefits of continuing pembrolizumab as post-neoadjuvant treatment in patients with triple-negative breast cancer (TNBC). Findings from the Phase III KEYNOTE-522 study (NCT03036488) of chemotherapy plus pembrolizumab in the neoadjuvant setting demonstrated the benefits of adding pembrolizumab. However, clinicians will need to be wary of financial toxicity that may be associated. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть